title: Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma.
authors.affiliation: Department of Medical Oncology and Bone Marrow Transplantation, Yale Cancer Center, New Haven, Connecticut 06520, USA. francine.foss@yale.edu
authors.forename: Francine
authors.initials: F
authors.lastname: Foss
authors.forename: Madeleine
authors.initials: M
authors.lastname: Duvic
authors.forename: Elise A
authors.initials: EA
authors.lastname: Olsen
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004167:Diphtheria Toxin / Q000008:administration & dosage*; D007376:Interleukin-2 / Q000008:administration & dosage*; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage; D012008:Recurrence; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D004167:Diphtheria Toxin; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox